Literature DB >> 10638996

Height-related risk factors for prostate cancer.

A E Norrish1, C U McRae, I M Holdaway, R T Jackson.   

Abstract

Previous studies have reported that adult height is positively associated with the risk of prostate cancer. The authors carried out a population-based case-control study involving 317 prostate cancer cases and 480 controls to further investigate the possibility that height is more strongly associated with advanced, compared with localized forms of this disease. Since the inherited endocrine factors, which in part determine height attained during the growing years, may influence the risk of familial prostate cancer later in life, the relationship with height was also investigated for familial versus sporadic prostate cancers. Adult height was not related to the risk of localized prostate cancer, but there was a moderate positive association between increasing height and the risk of advanced cancer (relative risk (RR) = 1.62; 95% confidence interval (CI) 0.97-2.73, upper versus lowest quartile, P-trend = 0.07). Height was more strongly associated with the risk of prostate cancer in men with a positive family history compared with those reporting a negative family history. The RR of advanced prostate cancer for men in the upper height quartile with a positive family history was 7.41 (95% CI 1.68-32.67, P-trend = 0.02) compared with a reference group comprised of men in the shortest height quartile with a negative family history. Serum insulin-like growth factor-1 levels did not correlate with height amongst men with familial or sporadic prostate cancers. These findings provide evidence for the existence of growth-related risk factors for prostate cancer, particularly for advanced and familial forms of this disease. The possible existence of inherited mechanisms affecting both somatic and tumour growth deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638996      PMCID: PMC2363202          DOI: 10.1054/bjoc.1999.0906

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Distribution of body weight and height: comparison of estimates based on self-reported and observed measures.

Authors:  W J Millar
Journal:  J Epidemiol Community Health       Date:  1986-12       Impact factor: 3.710

2.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells.

Authors:  P Cohen; D M Peehl; G Lamson; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1991-08       Impact factor: 5.958

3.  Animal fat consumption and prostate cancer: a prospective study in Hawaii.

Authors:  L Le Marchand; L N Kolonel; L R Wilkens; B C Myers; T Hirohata
Journal:  Epidemiology       Date:  1994-05       Impact factor: 4.822

4.  High birthweight as a predictor of prostate cancer risk.

Authors:  G Tibblin; M Eriksson; S Cnattingius; A Ekbom
Journal:  Epidemiology       Date:  1995-07       Impact factor: 4.822

5.  Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.

Authors:  A Juul; P Dalgaard; W F Blum; P Bang; K Hall; K F Michaelsen; J Müller; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

6.  Underestimation of relative weight by use of self-reported height and weight.

Authors:  A W Stewart; R T Jackson; M A Ford; R Beaglehole
Journal:  Am J Epidemiol       Date:  1987-01       Impact factor: 4.897

7.  Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty.

Authors:  B S Keenan; G E Richards; S W Ponder; J S Dallas; M Nagamani; E R Smith
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

8.  Evidence for a prostate cancer susceptibility locus on the X chromosome.

Authors:  J Xu; D Meyers; D Freije; S Isaacs; K Wiley; D Nusskern; C Ewing; E Wilkens; P Bujnovszky; G S Bova; P Walsh; W Isaacs; J Schleutker; M Matikainen; T Tammela; T Visakorpi; O P Kallioniemi; R Berry; D Schaid; A French; S McDonnell; J Schroeder; M Blute; S Thibodeau; H Grönberg; M Emanuelsson; J E Damber; A Bergh; B A Jonsson; J Smith; J Bailey-Wilson; J Carpten; D Stephan; E Gillanders; I Amundson; T Kainu; D Freas-Lutz; A Baffoe-Bonnie; A Van Aucken; R Sood; F Collins; M Brownstein; J Trent
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

9.  Comparison of self-reported and measured height and weight.

Authors:  M Palta; R J Prineas; R Berman; P Hannan
Journal:  Am J Epidemiol       Date:  1982-02       Impact factor: 4.897

10.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease.

Authors:  P Cohen; D M Peehl; H C Graves; R G Rosenfeld
Journal:  J Endocrinol       Date:  1994-09       Impact factor: 4.286

View more
  3 in total

1.  Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  J Ahn; S C Moore; D Albanes; W-Y Huang; M F Leitzmann; R B Hayes
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

2.  Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis.

Authors:  Luisa Zuccolo; Ross Harris; David Gunnell; Steven Oliver; Jane Athene Lane; Michael Davis; Jenny Donovan; David Neal; Freddie Hamdy; Rebecca Beynon; Jelena Savovic; Richard Michael Martin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

3.  Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Authors:  Artitaya Lophatananon; Sarah Stewart-Brown; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; David E Neal; Freddie C Hamdy; Jenny L Donovan; Graham G Giles; Liesel M Fitzgerald; Melissa C Southey; Paul Pharoah; Nora Pashayan; Henrik Gronberg; Fredrik Wiklund; Markus Aly; Janet L Stanford; Hermann Brenner; Aida K Dieffenbach; Volker Arndt; Jong Y Park; Hui-Yi Lin; Thomas Sellers; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Amanda Spurdle; Judith A Clements; Douglas Easton; Rosalind A Eeles; Kenneth Muir
Journal:  Br J Cancer       Date:  2017-08-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.